English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

REFERENCES 1. Platzbecker U. Treatment of MDS. Blood 2019;133:1096-107. 2. Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res 2014;38: 1381-91. 3. Voso MT, Niscola P, Piciocchi A, et al. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. Eur J Haematol 2016;96:344-51. 4. Tendas A, Lissia MF, Piccioni D, et al. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders. Support Care Cancer 2015;23:303-5. 5. Santini V. How I treat MDS after hypomethylating agent failure. Blood 2019;133:521-9. 6. Niscola P, Tendas A, Cupelli L, et al. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol 2015;133:64-6. 7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. 8. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9. 9. Niscola P, Neri B, Catalano G, et al. Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Acta Oncol 2017;56:1120-1. 10. Abruzzese E, Trawinska MM, Neri B, et al. Successful decitabine treatment in unfit, elderly patients with acute myeloid leukemia following chronic myeloproliferative neoplasm. Acta Haematol 2018;140:231-3. 11. Varaldo R, Raiola AM, Di Grazia C, et al. Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome. Am J Hematol 2017;92:E117-9. 12. Duong VH, Bhatnagar B, Zandberg DP, et al. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leuk Lymphoma 2015;56:1718-22. Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning

blood research

Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning